QPS Preclinical/Lab Services July 2025

Greetings!

Welcome to the Monthly QPS Preclinical Newsletter

This month, discover how QPS analyzes biomarkers to help determine drug safety and efficacy, learn why QPS is your ideal partner for CLIA-certified labs, and catch up on the latest scientific breakthroughs and insights on the QPS blog.

A Flexible Approach to Biomarker Capabilities

The goal of biomarker identification is to deliver on the promise of personalized medicine by understanding a patient’s unique clinical and genetic information. Incorporating a biomarker strategy through all phases of development can lead to improved commercial viability. QPS provides customers with state-of-the art services from preclinical studies through late phase global clinical trials, utilizing a broad range of bioanalytical techniques to identify biomarkers across a wide range of therapeutic areas.

Customer Testimonial

"I'd like to give you all my applause for your great work on completing the method. You have showed strong teamwork, excellent scientific skills and positive attitude during the entire time of the method validation."

Contact QPS for Biomarker Studies

CLIA Certified Laboratory Overview

QPS laboratories operate under CLIA regulations, where any entity performing even a single test on human specimens for clinical purposes must be certified.

QPS is accredited for CLIA high complexity testing in 49 states.

Reach Out To Discuss CLIA Sample Analysis

Discover the Future of Science on the QPS Blog

Injecting Hope: Early Steps Toward Prenatal Treatment for Genetic Disorders

The potential to treat severe genetic disorders before birth has taken a promising step forward. Researchers at the University of California, San Francisco (UCSF) are exploring the feasibility of injecting therapies directly into the...

In Utero Gene Therapies

Gene Therapy at QPS

Non-Opioid Painkiller Blocks Pain at its Source

Synthetic and semi-synthetic opioids offer powerful pain relief. Unfortunately, these drugs are also associated with negative outcomes, including addiction and overdose. The U.S. Centers for Disease Control and Prevention reported 48,422 deaths related to synthetic opioids in...

Non-opioids Offer Promising Results

Clinical Services at QPS

Subscribe to the QPS Blog

Visit our website www.qps.com

or contact us at infopr@qps.com

to start your next study.

www.qps.com | infopr@qps.com

We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)